Abstract
The Heart and Estrogen/Progestin Replacement Study (HERS) was the first randomised, double-blind, placebo-controlled study to evaluate the outcome of hormone replacement therapy (HRT) on subsequent cardiac events in postmenopausal women with established coronary heart disease (CHD). Of the 2763 women enrolled, 1380 were randomised to receive 0.625mg of conjugated equine estrogens plus 2.5mg of medroxyprogesterone daily (Prempro®) and 1383 were randomised to receive a placebo.
The results were surprising: 179 women in the hormone group and 182 women in the placebo group experienced either a nonfatal myocardial infarction or CHD death (relative hazard 0.99, 95% confidence interval 0.81 to 1.22). This occurred despite a net 11% reduction in low density lipoprotein (LDL) and a net 10% increase in high density lipoprotein (HDL) after 1 year of follow-up (p < 0.001 for LDL and HDL). Also, there were no differences between the 2 treatment groups in any secondary cardiovascular outcomes.
The overall null effect may have been the result of an unexpected early adverse effect of the HRT regimen that offset a later reduction in risk. Clearly, the use of HRT for secondary prevention of heart disease is more complex than was initially believed. More data are needed from other clinical trials concerning the risks and benefits of HRT to confirm or refute the puzzling HERS results. HERS also underscores the need for trials with clinical end-points to evaluate both the safety and efficacy of drug therapy. Although observational studies are useful, they cannot provide definitive answers regarding treatment recommendations. Until further data are available, clinicians should not use estrogen plus medroxyprogesterone for the sole purpose of secondary prevention of CHD.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
American Heart Association. Women and cardiovascular diseases biostatistical fact sheet. Available from: http://www.americanheart.org/statistics/biostats/biowo.htm [accessed 1999 Sep 22]
Wenger NK. Cardioprotection for the postmenopausal woman: HERS results and their implications. Prev Cardiol 1998; 1: 9–11
Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the nurses’ health study. N Engl J Med 1991; 325 (11): 756–62
Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117 (12): 1016–37
US Congress Office of Technology Assessment. Effectiveness and costs of osteoporosis screening and hormone replacement therapy: vol. II. Evidence of benefits, risks, and costs. Washington, DC: US Government Printing Office, 1995. Publ: OTA-BP-H-144
Sullivan JM, Vander Zwaag R, Hughes JP, et al. Estrogen replacement and coronary artery disease: effect on survival in postmenopausal women. Arch Intern Med 1990; 150 (12): 2557–62
Sullivan JM, El-Zeky F, Vander Zwaag R, et al. Effect on survival of estrogen replacement therapy after coronary artery bypass grafting. Am J Cardiol 1997; 79 (7): 847–50
O’Keefe Jr JH, Kim SC, Hall RR, et al. Estrogen replacement therapy after coronary angioplasty in women. J Am Coll Cardiol 1997; 29 (1): 1–5
O’Brien JE, Peterson ED, Keeler GP, et al. Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions. J Am Coll Cardiol 1996; 28 (5): 1111–8
Newton KM, LaCroix AZ, McKnight B, et al. Estrogen replacement therapy and prognosis after first myocardial infarction. Am J Epidemiol 1997; 145 (3): 269–77
Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ 1997; 315: 149–53
Sidney S, Petitti DB, Quesenberry Jr CP. Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women. Ann Intern Med 1997; 127 (7): 501–8
Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280 (7): 605–13
The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 1995; 273 (3): 199–208
Adams MR, Register TC, Golden DL, et al. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17 (1): 217–21
Grodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348 (9033): 983–7
Psaty BM, Heckbert SR, Atkins D, et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med 1994; 154 (12): 1333–9
Falkeborn M, Persson I, Adami HO, et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol 1992; 99 (10): 821–8
Rosenberg L, Palmer JR, Shapiro S. A case-control study of myocardial infarction in relation to use of estrogen supplements. Am J Epidemiol 1993; 137 (1): 54–63
Stadel BV. Oral contraceptives and cardiovascular disease. N Engl J Med 1981; 305 (11) Pt 1: 612–8
Suissa S, Blais L, Spitzer WO, et al. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997; 56 (3): 141–6
Shapiro S, Slone D, Rosenberg L, et al. Oral-contraceptive use in relation to myocardial infarction. Lancet 1979; I: 743–7
Vandenbroke JP, Koster T, Briet E, et al. Increased risk of venous thrombosis in oral contraceptive users who are carriers of the Factor V Leiden mutation. Lancet 1994; 344: 1453–7
Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332 (8): 481–7
Williams JK, Sukhova GK, Herrington DM, et al. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 1998; 31: 684–91
Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998; 81 (4A): 7–12B
Women’s Health Initiative Study Group. Design of the women’s health initiative clinical trial and observational study. Control Clin Trials 1998; 19: 61–109
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wells, G., Herrington, D.M. The Heart and Estrogen/Progestin Replacement Study. Drugs & Aging 15, 419–422 (1999). https://doi.org/10.2165/00002512-199915060-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002512-199915060-00001